The field of medicine is taking its first steps towards patient-specific care. Research is aimed at tailoring treatments to address each person’s individualized needs and unique disease presentation. Scientists are developing nanoparticles that target disease sites, where they perform a programmed therapeutic task. These systems utilize molecular-machines and cellular recognition to improve efficacy and reduce side effects.
Avi Schroeder is a tenured Associate Professor of Chemical Engineering at the Technion – Israel Institute of Technology, where he heads the Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies.